Relay Therapeutics (RLAY) Stock Price
Relay Therapeutics Price
Revenue at Relay Therapeutics has contracted by 28.6% per year over the past 5 years to 15.36 M USD. Relay Therapeutics's net margin stands at -1,800.6%, up from -12,012.9% several years earlier. Analysts set a median price target of 27.00 USD, implying 50.4% above the current price. Of 20 analysts, 19 rate the stock a buy — an overall Buy consensus.
Relay Therapeutics stock price
Relay Therapeutics business model & stock analysis
Frequently asked questions about Relay Therapeutics
Relay Therapeutics Inc's business model focuses on leveraging advanced technologies to transform drug discovery and development. As a biotechnology company, Relay Therapeutics employs an innovative approach that combines computational techniques, biophysical insights, and deep experience in structural biology to design and develop potential therapeutics. By constructing accurate 3D models of proteins, Relay Therapeutics aims to uncover critical information about their function and dysfunction, driving the discovery of novel medicines. The company's business model revolves around applying this cutting-edge platform to identify and advance promising drug candidates, with a particular emphasis on targeted protein degradation and allosteric modulation. Relay Therapeutics Inc strives to address unmet medical needs and improve patient outcomes through its unique, technology-driven approach in drug discovery.
Relay Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Relay Therapeutics Inc in the market include companies such as Vertex Pharmaceuticals, Inc., Beam Therapeutics Inc., and Nurix Therapeutics Inc.
Relay Therapeutics Inc. is a biotechnology company that focuses on discovering and developing new medicines to potentially treat cancer and other diseases. Founded in 2016, Relay Therapeutics combines the fields of computation and experimental biology to design innovative therapies. The company's platform integrates advanced technology, including artificial intelligence and machine learning, to gain a deeper understanding of protein motion and its role in diseases. By leveraging this expertise, Relay Therapeutics aims to discover drugs that can effectively target specific proteins and improve patient outcomes. With its commitment to scientific excellence and cutting-edge research, Relay Therapeutics is dedicated to revolutionizing the field of drug discovery.
Relay Therapeutics Inc has achieved several significant milestones since its inception. This biotechnology company has successfully built a proprietary drug discovery platform that combines computation and experimental approaches to design new small molecule therapies. In 2020, Relay Therapeutics raised approximately $400 million in its initial public offering (IPO), indicating strong market interest in its innovative capabilities. Furthermore, the company has established strategic collaborations with renowned organizations like Genentech and Eli Lilly to accelerate the development of potential breakthrough medicines. These achievements highlight Relay Therapeutics Inc's commitment to revolutionize drug discovery through its cutting-edge platform and strategic partnerships.
Relay Therapeutics Inc is primarily present in the United States.
Relay Therapeutics Inc represents the values of innovation, collaboration, and patient-centricity. The company's corporate philosophy is centered around leveraging the power of protein motion to discover new medicines for patients. Relay Therapeutics is committed to fostering a culture of inclusivity and diversity, empowering its employees to think creatively and work collaboratively towards its mission. By combining cutting-edge technology and deep expertise in structural biology, the company strives to unlock novel insights into protein motion and develop transformative therapies. Relay Therapeutics Inc is dedicated to improving the lives of patients by translating scientific discoveries into impactful medicines.
Analysts currently set an average price target of 26.13 USD for the Relay Therapeutics stock (median: 27.00 USD), implying +45.6 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the Relay Therapeutics stock: 19 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Relay Therapeutics to generate revenue of 11.16 M USD and earnings per share of -1.33 USD.
Converted at the current exchange rate, the Relay Therapeutics share trades at 16.03 EUR (17.95 USD).
The Relay Therapeutics share (RLAY) is listed on 1 stock exchanges, including: NASDAQ (RLAY).
Relay Therapeutics is an innovative biotechnology company focused on the discovery and development of new drugs for serious diseases. The company was founded in 2016 and uses a unique computer-based approach to identify new targets for drugs. The company concentrates on developing drugs for diseases that currently lack effective treatments. It employs a computer-based approach to identify new targets for drugs. Relay Therapeutics has developed an innovative technology platform that combines synthetic chemistry and modern biology. Relay Therapeutics offers a wide range of products and services to its customers. The company utilizes a dynamic and customer-centric business strategy, ensuring that it meets the needs of its customers while remaining innovative. Collaborating with other companies and institutions to leverage its technology and expertise and develop innovative products and services is a crucial component of Relay Therapeutics' business model. The company partners with other companies and universities to develop innovative drugs and diagnostic procedures. Relay Therapeutics has already established successful partnerships with major pharmaceutical companies such as Sanofi and Vertex Pharmaceuticals, as well as other industry leaders. Relay Therapeutics has built a strong pipeline of projects focusing on the development of new drugs. Its research programs concentrate on developing drugs for cancer, neurodegenerative diseases, and rare diseases. Furthermore, Relay Therapeutics also relies on strategic partnerships to expand its product pipeline and enter new markets. The company has already established successful partnerships with major pharmaceutical companies such as Sanofi and Vertex Pharmaceuticals, as well as other industry leaders. The business model of Relay Therapeutics is based on the following key components: - Utilization of technology platforms: Relay Therapeutics utilizes state-of-the-art computer-based technology platforms to identify new targets for drugs. - Focus on serious diseases: Relay Therapeutics focuses on developing drugs for serious diseases that currently lack effective treatments. - Collaboration with other companies and institutions: Relay Therapeutics collaborates with other companies and institutions to leverage its technology and expertise in developing innovative products and services together. - Wide range of products and services: Relay Therapeutics offers a wide range of products and services tailored to the needs of its customers. Overall, Relay Therapeutics employs a collaborative business strategy to develop innovative drugs for serious diseases. With its technology platforms, research programs, and strategic partnerships, the company has gained a strong position in the biotechnology industry and is well-positioned to continue developing innovative solutions for the healthcare sector.
The expected revenue of Relay Therapeutics is 11.16 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Relay Therapeutics is -228.82 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Relay Therapeutics is currently -13.46. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Relay Therapeutics stock.
The price-to-sales ratio (P/S) of Relay Therapeutics is currently 275.98. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Relay Therapeutics stock.
The Eulerpool Quality Score for Relay Therapeutics is 3/10.
The ISIN of Relay Therapeutics is US75943R1023. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Relay Therapeutics is A2P9AA. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Relay Therapeutics is RLAY. The ticker symbol is used to trade Relay Therapeutics shares on the stock exchange.
Relay Therapeutics stock
Relay Therapeutics Peer Group
Relay Therapeutics Ticker
Relay Therapeutics FIGI
All fundamentals and in-depth analysis of Relay Therapeutics
Our stock analysis for Relay Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Relay Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.